Isavuconazonium
- Generic Name
- Isavuconazonium
- Brand Names
- Cresemba
- Drug Type
- Small Molecule
- Chemical Formula
- C35H35F2N8O5S
- CAS Number
- 742049-41-8
- Unique Ingredient Identifier
- VH2L779W8Q
- Background
Isavuconazonium is a second-generation triazole antifungal approved on March 6, 2015 by the FDA for the treatment of invasive aspergillosis and invasive mucormycosis, marketed by Astellas under the brand Cresemba. It is the prodrug form of isavuconazole, the active moiety, and it is available in oral and parenteral formulations. Due to low solubility in wate...
- Indication
Indicated in the treatment of invasive aspergillosis and invasive mucormycosis.
- Associated Conditions
- Disseminated mucormycosis, Invasive Aspergillosis
- Associated Therapies
- -
Drug Interaction Study of Isavuconazole and Midazolam
- Conditions
- Interventions
- First Posted Date
- 2011-08-01
- Last Posted Date
- 2011-08-01
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 24
- Registration Number
- NCT01406171
- Locations
- ๐บ๐ธ
Covance Clinical Research, Madison, Wisconsin, United States
Isavuconazole in the Treatment of Renally Impaired Aspergillosis and Rare Fungi
- First Posted Date
- 2008-03-12
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 149
- Registration Number
- NCT00634049
- Locations
- ๐บ๐ธ
UMASS Memorial Medical Center, Worcester, Massachusetts, United States
๐บ๐ธCleveland Clinic, Cleveland, Ohio, United States
๐บ๐ธUpstate Infectious Diseases Association LLP, Albany, New York, United States
Isavuconazole (BAL8557) for Primary Treatment of Invasive Aspergillosis
- Conditions
- Interventions
- First Posted Date
- 2006-12-19
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 527
- Registration Number
- NCT00412893
- Locations
- ๐ฆ๐ท
Hospital Italiano de Buenos Aires, Ciudad Autonoma, Argentina
๐บ๐ธUniversity of Alabama, Birmingham, Alabama, United States
๐บ๐ธUniversity of Chicago, Division of Infectious Diseases, Chicago, Illinois, United States
Safety, Efficacy and Pharmacokinetics of an Antifungal in Patients Undergoing Chemotherapy
- First Posted Date
- 2006-12-19
- Last Posted Date
- 2023-05-10
- Lead Sponsor
- Basilea Pharmaceutica
- Target Recruit Count
- 18
- Registration Number
- NCT00413439
- Locations
- ๐ฉ๐ช
University Cologne, Cologne, Germany
Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida Infections
- Conditions
- Interventions
- First Posted Date
- 2006-12-19
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 450
- Registration Number
- NCT00413218
- Locations
- ๐บ๐ธ
Idaho Falls Infectious Diseases PLLC, Idaho Falls, Idaho, United States
๐บ๐ธSomero Research Corporation, Palm Desert, California, United States
๐บ๐ธLoyola University Hospital, Maywood, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.